Literature DB >> 15520785

Short-term safety assessment in the use of intravenous zoledronic acid in children.

Wolfgang Högler1, Fabian Yap, David Little, Geoffrey Ambler, Mary McQuade, Christopher T Cowell.   

Abstract

The clinical side effects of the potent new bisphosphonate zoledronic acid in children are unknown. In this study of 34 children with various bone disorders, the frequency of postinfusion flu-like illness, hypocalcemia, and hypophosphatemia was 85%, 74%, and 82%, respectively. No renal side effects were detected after up to 3 consecutive infusions.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15520785     DOI： 10.1016/j.jpeds.2004.06.066

Source DB:  PubMed          Journal:  J Pediatr        ISSN： 0022-3476            Impact factor:   4.406


  17 in total

1.  Periosteal grafting for congenital pseudarthrosis of the tibia: a preliminary report.

Authors:  Ahmed M Thabet; Dror Paley; Mehmet Kocaoglu; Levent Eralp; John E Herzenberg; Omer Naci Ergin
Journal:  Clin Orthop Relat Res       Date:  2008-10-25       Impact factor: 4.176

Review 2.  Zoledronic acid in pediatric metabolic bone disorders.

Authors:  Sasigarn A Bowden; John D Mahan
Journal:  Transl Pediatr       Date:  2017-10

3.  A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study.

Authors:  Heidi V Russell; Susan G Groshen; Tasnim Ara; Yves A DeClerck; Randy Hawkins; Hollie A Jackson; Heike E Daldrup-Link; Araz Marachelian; Andrej Skerjanec; Julie R Park; Howard Katzenstein; Katherine K Matthay; Susan M Blaney; Judith G Villablanca
Journal:  Pediatr Blood Cancer       Date:  2010-11-12       Impact factor: 3.167

4.  Relationship between postoperative complications and fibular integrity in congenital pseudarthrosis of the tibia in children.

Authors:  Yao-Xi Liu; Hai-Bo Mei; Guang-Hui Zhu; Rong-Guo He; Kun Liu; Jin Tang; Jiang-Yan Wu; Wei-Hua Ye; Xin Hu; Qian Tan; An Yan; Sheng-Xiang Huang; Xiao-Qian Tan; Ting Lei
Journal:  World J Pediatr       Date:  2016-12-23       Impact factor: 2.764

5.  Severe non-infective systemic inflammatory response syndrome, shock, and end-organ dysfunction after zoledronic acid administration in a child.

Authors:  S Trivedi; A Al-Nofal; S Kumar; S Tripathi; R J Kahoud; P J Tebben
Journal:  Osteoporos Int       Date:  2016-02-18       Impact factor: 4.507

6.  Sustained beneficial effect of intravenous bisphosphonates after their discontinuation in children.

Authors:  Kim M Waterhouse; Ari Auron; Tarak Srivastava; Connie Haney; Uri S Alon
Journal:  Pediatr Nephrol       Date:  2006-10-11       Impact factor: 3.714

Review 7.  Protecting Bone Health in Pediatric Rheumatic Diseases: Pharmacological Considerations.

Authors:  Yujuan Zhang; Diana Milojevic
Journal:  Paediatr Drugs       Date:  2017-06       Impact factor: 3.022

Review 8.  Systematic review of effectiveness of bisphosphonates in treatment of low bone mineral density and fragility fractures in juvenile idiopathic arthritis.

Authors:  J Thornton; D M Ashcroft; M Z Mughal; R A Elliott; T W O'Neill; D Symmons
Journal:  Arch Dis Child       Date:  2006-05-11       Impact factor: 3.791

9.  Short-Term Safety of Zoledronic Acid in Young Patients With Bone Disorders: An Extensive Institutional Experience.

Authors:  Sobenna George; David R Weber; Paige Kaplan; Kelly Hummel; Heather M Monk; Michael A Levine
Journal:  J Clin Endocrinol Metab       Date:  2015-08-26       Impact factor: 5.958

Review 10.  Osteoporosis in paediatric patients with spina bifida.

Authors:  Humberto Marreiros; Humberto Filipe Marreiros; Clara Loff; Eulalia Calado
Journal:  J Spinal Cord Med       Date:  2012-01       Impact factor: 1.985
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.